

22 May 2015 |

ASCO 2015: Pre-conference review

by Lucie Ellis-Taitt

In this roundtable *The Pink Sheet's* Mary Jo Laffler talks to experts from Datamonitor Healthcare, Citeline and BioMedTracker about their top picks from this year's ASCO abstracts, as well as other news to watch out for at the 2015 conference at the end of this month.

In this roundtable *The Pink Sheet's* Mary Jo Laffler talks to experts from Datamonitor Healthcare, Citeline and BioMedTracker about their top picks from this year's ASCO abstracts, as well as other news to watch out for at the 2015 conference at the end of this month.

They discuss highlights in the area of immune-oncology, specifically new combination drug candidates; game-changing data expected for myeloma therapies; how companies are looking at new approaches for old targets in oncology; and more.

Click here to explore this interactive content online

ASCO 2015 Pre-Conference Review from *Datamonitor Healthcare* on *Vimeo*.

Related stories:

Big pharma's immunotherapy game at ASCO

Good, Bad, Ugly: the ASCO abstracts are out

For more coverage on ASCO 2015:

www.scripintelligence.com

www.biomedtracker.com



www.datamonitorhealthcare.com

www.citeline.com

The Pink Sheet